Back
PTC Therapeutics 10K Form
Sell
43
PTCT
PTC Therapeutics
Last Price:
42.81
Seasonality Move:
30.95%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-04-25 | 10Q | PTCT/PTC Therapeutics Quarterly |
2023-10-26 | 10Q | PTCT/PTC Therapeutics Quarterly |
2023-08-03 | 10Q | PTCT/PTC Therapeutics Quarterly |
2023-04-27 | 10Q | PTCT/PTC Therapeutics Quarterly |
2022-10-27 | 10Q | PTCT/PTC Therapeutics Quarterly |
2022-08-04 | 10Q | PTCT/PTC Therapeutics Quarterly |
Receive PTCT News And Ratings
See the #1 stock for the next 7 days that we like better than PTCT
PTCT Financial Statistics
Sales & Book Value
Annual Sales: | $937.82M |
---|---|
Cash Flow: | $-64.08M |
Price / Cash Flow: | 0 |
Annual Sales: | $-12.75 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -6.31000 |
---|---|
Net Income (TTM): | $-479.52M |
Gross Margin: | $872.34M |
Return on Equity: | 0% |
Return on Assets: | -29.24% |
PTC Therapeutics Earnings Forecast
Key PTC Therapeutics Financial Ratios
- The Gross Profit Margin over the past 11 years for PTCT is 93.02%.
- The Selling, General & Administrative Expenses for PTCT have been equal to 35.46% of Gross Profit Margin.
- The Research & Development expenses have been 71.08% of Revenue.
- The Interest Expense is -20.62% of Operating Income.
- The Net Earning history of PTCT is -66.81% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 4 years.
PTC Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | PTCT |
CUSIP: | 69366J |
Website: | ptcbio.com |
Debt
Debt-to-Equity Ratio: | -0.29 |
---|---|
Current Ratio: | 2.23 |
Quick Ratio: | 2.1 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
PTCT Technical Analysis vs Fundamental Analysis
Sell
43
PTC Therapeutics (PTCT)
is a Sell
Is PTC Therapeutics a Buy or a Sell?
-
PTC Therapeutics stock is rated a Sell
The current PTC Therapeutics [PTCT] share price is $40.87. The Score for PTCT is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.